Table 3 Overview of hypofractionated radiotherapy for prostate cancer
Author(s) (year) [Referense no.] | Arcangeli G (2011)[11] | Fonteyne et al. (2012)[12] | Kupelian et al. (2007)[9] | Dearnaley et al. (2012)[13] | Corrent study (2014) | ||
|---|---|---|---|---|---|---|---|
Nominal dose (Gy)/no. of fractions | 62/20 | 56/16 | 70/28 | 60/20 | 57/19 | 70/30 | |
Number of patients | 83 | 113 | 770 | 153 | 151 | 110 | |
Follow-up period (months) | 35 | 47 | 45 | 51 | 31 | ||
CTV for T1-2 & low risk | Prostate & seminal vesicles | Prostate only | Prostate only | Prostate + base of seminal vesicles | Prostate only | ||
CTV for T3 & high risks | Prostate & seminal vesicles | Prostate & seminal vesicles | Prostate & seminal vesicles | Prostate & seminal vesicles | |||
PTV margin (mm) | Craniocaudal | 10 | 3-10 | 5 | 5 | 5 | 3 |
Anterior | 10 | 5 | 5 | 5 | 3 | ||
Lateral | 10 | 8 | 5 | 5 | 3 | ||
Posterior | 6 | 4 | 0 | 0 | 3 | ||
Early GU (%) | G2 | 46 | 38 | 18 | 8 | 7 | 1 |
G3 | 1 | 0 | 1 | 0 | 0 | 0 | |
G4 | 0 | 0 | 0 | 0 | 0 | ||
Early GI (%) | G2 | 35 | 10 | 9 | 2 | 1 | 0 |
G3 | 0 | 4 | 0 | 0 | 0 | 0 | |
G4 | 0 | 0 | 0 | 0 | 0 | ||
Late GU (%) | G2 | 8 | 10 | 5 | 2 | 0 | 3 |
G3 | 0 | 4 | 1 | 0 | 0 | 0 | |
G4 | 1 | 0 | 0 | 0 | 0 | ||
Late GI (%) | G2 | 14 | 7 | 3 | 4 | 1 | 0 |
G3 | 1 | 2 | 1 | 0 | 0 | 0 | |
G4 | 0 | 0 | 0 | 0 | 0 | ||
Biochemical relapse free survival 5 yrs (3 yrs) % | Low | - | 98 | 94 | - | - | 100 (100) |
Intermediate | - | 93 | 83 | - | - | 84 (94) | |
High | - | 82 | 72 | - | - | 80 (90) | |